Drugs / GSK1795091
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03447314 | Mar 2018 → Jul 2020 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02798978 | Jan → Oct 2017 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1795091 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03447314 ↗ |
| Known as | CRX-601 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802207 ↗ |
| Action | Activate | “TLR4 Agonist (GSK1795091)” NCT02798978 ↗ |
| Route | Intravenous | “administered as IV bolus over 2-5 minutes (min)” NCT02798978 ↗ |
| Target | TLR4 | “TLR4 Agonist (GSK1795091)” NCT02798978 ↗ |